EUVIMEDEUVIMED entdecken
Crossref

A 10-year (2013–2023) analysis of incidence, etiology and mortality of acute pancreatitis in England

James Lucocq, Fraser Barbour, Kim Keltie, Edward O'Toole, Manu Nayar, Sanjay Pandanaboyana

HPB · 2025

DOI: 10.1016/j.hpb.2025.02.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HPB, 2025. Verfasst von James Lucocq und 5 weiteren Autor:innen. Beteiligte Einrichtung: Royal Infirmary of Edinburgh, Edinburgh, UK. Electronic address: james.lucocq@nhs.scot. Hauptthemen laut MEDLINE: Pancreatitis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The aim of the present study was to report epidemiological data on the incidence of acute pancreatitis (AP) in England between 2013 and 2023 and report contemporary post-AP outcomes. METHODS: A search of patients admitted with AP (2013-2023) was performed within the Hospital Episode Statistics (HES) which covers all admitted patients within England using diagnosis (ICD-10) code K85. RESULTS: A total of 260,009 patients (median age, 59 years; IQR, 30; F:M, 1.02:1) were identified from 185 NHS trusts (2013-2023), with an incidence of 456 cases per million and an annual increase of 2.6 %. A total of 8.0 % patients required ITU admission. The AP readmission rate was 30.2 % after a median follow-up time of 45 months (Q1-Q3, 17-80 months). The in-hospital mortality rate was 4.5 % (n = 11,711). The overall survival at 1, 2, 5 and 10 years was 88.9 [95%CI 88.7,89], 85.2 [85.1,85.4], 76.1 [75.9,76.3] and 63.9 [63.6,64.2]. Long-term survival (10-year) was higher with biliary aetiology (p < 0.01), younger age groups (p < 0.05) and those without ITU admission (p < 0.01). CONCLUSIONS: The incidence of AP in England is increasing and in-hospital mortality rates remain significant. These findings have implications for resource allocation to mitigate risk factors for developing AP in addition to the need for long-term follow-up for at-risk groups. CLINICAL TRIAL REGISTRATION: N/A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PancreatitisHumansEnglandIncidenceMiddle AgedMaleFemaleAgedAdultHospital MortalityAcute DiseaseTime FactorsRisk FactorsPatient Readmission

Autor:innen und Institutionen

  • Royal Infirmary of Edinburgh, Edinburgh, UK. Electronic address: james.lucocq@nhs.scot.
  • Freeman Hospital, Newcastle upon-Tyne, UK.
  • Freeman Hospital, Newcastle upon-Tyne, UK; Population Health Sciences Institute, Newcastle University, UK.

Zitieren

APA

Lucocq, J., Barbour, F., Keltie, K., O'Toole, E., Nayar, M., & Pandanaboyana, S. (2025). A 10-year (2013–2023) analysis of incidence, etiology and mortality of acute pancreatitis in England. HPB. https://doi.org/10.1016/j.hpb.2025.02.003

Vancouver

Lucocq J, Barbour F, Keltie K, O'Toole E, Nayar M, Pandanaboyana S. A 10-year (2013–2023) analysis of incidence, etiology and mortality of acute pancreatitis in England. HPB. 2025. doi:10.1016/j.hpb.2025.02.003

BibTeX
@article{Lucocq2025,
  author = {Lucocq, James and Barbour, Fraser and Keltie, Kim and O'Toole, Edward and Nayar, Manu and Pandanaboyana, Sanjay},
  title = {A 10-year (2013–2023) analysis of incidence, etiology and mortality of acute pancreatitis in England},
  journal = {HPB},
  year = {2025},
  doi = {10.1016/j.hpb.2025.02.003}
}
Kostenlos starten →